|Access to this symposium is free, but you must first be a
registered FREE ZONE user of HDCN. If not already an HDCN FREE ZONE user, please
register at this link and select a username and password.
| After participating in this program, the learner should be able to:
- Discuss recent data in treating PD and CKD patients with newer IV iron therapies.
- Discuss current practices in caring for ESRD patients with iron deficiency anemia.
- Identify safe and effective treatment options for improving ESRD patient outcomes.
Vaughn W. Folkert, MD.
Director, Baumritter Kidney Center
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York
Asuncion M. Javier, RN, BSN
Clinical Nurse Consultant
University of Illinois at Chicago
Neeta B. O'Mara, PharmD, BCPS
Dialysis Clinic, Inc.
North Brunswick, New Jersey
The series of talks is approved for
1.7 Contact Hours by the American Nephrology Nurses' Association (ANNA)
Date of Original Release: August 17, 2002
CE Credit Eligible Through: August 17, 2003
Contact Hours/Completion Time: 1.7
Target Audiences: Nephrology nurses and
Method of participation: Listen to the talk, read the PubMed
abstracts linked to data slides and talk references, take the post-test, read
the linked abstracts in the post-test, answer feedback material.
Chronic kidney disease affects 30-40 million Americans, of whom
several hundred thousand require renal replacement therapy. These
will allow nephrology nurses, pharmacists, and technicians to obtain
up-to-date information about issues related to care of renal patients.
This continuing education activity is based on an approved Satellite Symposium which took place at the American Nephrology Nurses' Association (ANNA) 2002 Annual Meeting, and is approved by ANNA,
East Holley Avenue, Box 56, Pitman, New Jersey 08071-0056, an accredited approver by the American Nurse Credentialing Center Commission on Accreditation (ANCC-COA). ANNA is an approved provider of CE
to nursing by the California Board of Registered Nursing, BRN Provider No. 00910, the Alabama Board of Nursing, BRN Provider No. PO324, and the Kansas State Board of Nursing, Provider No. LT0148-0738.
This course offering is applicable for RN and LPN licensure in Kansas. Licensees in the states of CA, AL, and KS must retain this certificate for four years after the CE activity is completed. Other
mandatory CE states may have different record keeping requirements. Please be aware of your state's procedure.
The activity provider is HDCN, 15W560 89th St., Hinsdale, IL 60527.
The American Nephrology Nurses' Association, as well as HDCN have conflict of
interest policies that require course faculty to disclose
any real or apparent commercial financial affiliations related to the
content of their presentations/materials. It is not assumed that these
financial interests or affiliations will have an adverse
impact on faculty presentations; they are simply noted here to fully inform
FACULTY DISCLOSURE STATEMENTS
V. Folkert is a speakers' bureau participant for Ortho Biotech and Watson Pharma Inc.
A. M. Javier has received grants/research support from Ortho Biotech and is a speakers' bureau participant for Watson Pharma Inc.
N. O'Mara is a stock/shareholder in BMS, Pfizer, Merck, and Wyeth and is a speakers' bureau participant for Genentech and American Bone Care.
educational activity may contain discussion of published
investigational uses of agents that are not indicated by
The American Nephrology Nurses' Association, and HDCN do not
recommend the use of any agent outside of the labeled
Please refer to the official prescribing information for
product for discussion of approved indications,
DISCLOSURE OF UNLABELED USE:
have an implied responsibility to use the newly acquired
to enhance patient outcomes and their own professional
The information presented in this activity is not meant
to serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment
discussed or suggested in this activity should not be used by clinicians
without evaluation of their patient's conditions and possible
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.